title: [Regorafenib in patients with metastatic colorectal cancer: a review and an update].
abstract: Standard chemotherapy in patients with metastatic colorectal cancer is based on a combination of fluoropyrimidines, irinotecan and oxaliplatin. Regorafenib, an oral multikynase inhibitor blocking multiple disease progression-involved pathways, is a new therapeutic option in patients who already received standard therapy. In a phase III randomized, placebo-controlled study regorafenib, as compared to best supportive care, showed a statistically significant improvement in overall survival, irrespective of KRAS mutation status. Safety profile of regorafenib is acceptable, with few severe grade adverse events which can be adequately managed within few weeks after treatment beginning. Regorafenib is a new treatment standard in patients who already received chemotherapy for metastatic colorectal cancer.
authors.forename: Alberto
authors.initials: A
authors.lastname: Zaniboni
authors.forename: Giovanni
authors.initials: G
authors.lastname: Mansueto
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage* / Q000009:adverse effects; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D006801:Humans; D009154:Mutation; D009362:Neoplasm Metastasis; D010671:Phenylurea Compounds / Q000008:administration & dosage* / Q000009:adverse effects; D016283:Proto-Oncogene Proteins p21(ras) / Q000235:genetics; D011725:Pyridines / Q000008:administration & dosage* / Q000009:adverse effects; D016032:Randomized Controlled Trials as Topic; D015996:Survival Rate
chemical_list: C117307:KRAS protein, human; D010671:Phenylurea Compounds; D011725:Pyridines; C559147:regorafenib; D016283:Proto-Oncogene Proteins p21(ras)